Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains why he believes that all metastatic castration-resistant prostate cancer patients should receive chemotherapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Who are the right metastatic castration-resistant prostate cancer patients that should be treated with chemotherapy
Advertisement